Uncategorized

• Uncategorized

  Gradient Denervation Technologies Announces Acceptance into FDA’s Total Product Life Cycle Advisory Program for Development of its Pulmonary Artery Denervation System

  Continue reading

• Uncategorized

  Gradient Denervation Technologies Announces FDA Breakthrough Designation for Pulmonary Artery Denervation System

  Continue reading

• Uncategorized

  Gradient Denervation Technologies Appoints Stanton Rowe to Board of Directors and Receives FDA Approval to Expand Early Feasibility Study

  Continue reading

• Uncategorized

  Gradient Denervation Technologies Enrolls First Patient in Early Feasibility Study of Pulmonary Artery Denervation System

  Continue reading

• Uncategorized

  Gradient Denervation Technologies closes €14m Series A led by Sabadell Asabys

  Continue reading

• Uncategorized

  Gradient Denervation Technologies enrolls initial patient in first-in-human study of pulmonary artery denervation technology

  Continue reading

• Uncategorized

  Gradient Denervation Technologies announces appointment of Martin Grasse as Chief Executive Officer

  Continue reading

• Uncategorized

  Gradient Denervation Technologies Raises €3.5M in Seed Funding with Sofinnova Partners

  Continue reading